Literature DB >> 7588746

Regulation of rat mast cell protease 1 activity. Protease inhibition is prevented by heparin proteoglycan.

G Pejler1, L Berg.   

Abstract

Rat mast cell protease 1 (RMCP-1) is a chymotrypsin-like serine protease (chymase) that is specifically expressed by connective-tissue-type mast cells. It is stored in the secretory granules of the cells in a complex with heparin proteoglycan, and the chymase/heparin proteoglycan complexes are released following mast cell activation. The present study was undertaken to examine if the association with heparin proteoglycan influenced the regulation of RMCP-1 by various macromolecular protease inhibitors. Endogenous mast cell heparin proteoglycan was shown to significantly block the inhibition of RMCP-1 by the serpins alpha 1-protease inhibitor and alpha 1-antichymotrypsin, as well as the inhibition by alpha 2-macroglobulin, soybean trypsin inhibitor and plasma. The blocking of protease inhibition showed an optimum at a RMCP-1/proteoglycan ratio of 5:1 (by mass), corresponding to approximately 80 RMCP-1 molecules bound/proteoglycan molecule. Chymase activity present on intact peritoneal mast cells, i.e. present in its native complex with heparin proteoglycan, was also shown to be largely resistant to inhibition by alpha 1-antichymotrypsin and alpha 1-protease inhibitor. Heparin 10-saccharides and 20-saccharides were inefficient in preventing the interaction of RMCP-1 with alpha 1-antichymotrypsin, whereas pig mucosal heparin (approximately 50 monosaccharide units) blocked protease inhibition. We have previously shown that heparin potentiates the catalytic activity of RMCP-1 and, in the present study, we show that the mechanism for chymase activation involves a sixfold reduction of the Km,app value of RMCP-1 for the chromogenic substrate S-2586. Thus, the association of mast cell chymase with heparin proteoglycan may serve both to potentiate the catalytic activity of the enzyme and to increase the life-span of the chymases by preventing their inhibition after exocytosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7588746     DOI: 10.1111/j.1432-1033.1995.192_1.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  8 in total

Review 1.  Intracellular proteoglycans.

Authors:  Svein Olav Kolset; Kristian Prydz; Gunnar Pejler
Journal:  Biochem J       Date:  2004-04-15       Impact factor: 3.857

Review 2.  Mast cell proteoglycans.

Authors:  Elin Rönnberg; Fabio R Melo; Gunnar Pejler
Journal:  J Histochem Cytochem       Date:  2012-08-16       Impact factor: 2.479

Review 3.  Regulation and function of mast cell proteases in inflammation.

Authors:  C Huang; A Sali; R L Stevens
Journal:  J Clin Immunol       Date:  1998-05       Impact factor: 8.317

Review 4.  Insights into the key roles of proteoglycans in breast cancer biology and translational medicine.

Authors:  Achilleas D Theocharis; Spyros S Skandalis; Thomas Neill; Hinke A B Multhaupt; Mario Hubo; Helena Frey; Sandeep Gopal; Angélica Gomes; Nikos Afratis; Hooi Ching Lim; John R Couchman; Jorge Filmus; Ralph D Sanderson; Liliana Schaefer; Renato V Iozzo; Nikos K Karamanos
Journal:  Biochim Biophys Acta       Date:  2015-03-28

Review 5.  Tissue-specific expression of mast cell granule serine proteinases and their role in inflammation in the lung and gut.

Authors:  Hugh R P Miller; Alan D Pemberton
Journal:  Immunology       Date:  2002-04       Impact factor: 7.397

Review 6.  Cell-matrix interactions: focus on proteoglycan-proteinase interplay and pharmacological targeting in cancer.

Authors:  Achilleas D Theocharis; Chrisostomi Gialeli; Panagiotis Bouris; Efstathia Giannopoulou; Spyros S Skandalis; Alexios J Aletras; Renato V Iozzo; Nikos K Karamanos
Journal:  FEBS J       Date:  2014-11-06       Impact factor: 5.542

7.  Lactoferrin regulates the activity of heparin proteoglycan-bound mast cell chymase: characterization of the binding of heparin to lactoferrin.

Authors:  G Pejler
Journal:  Biochem J       Date:  1996-12-15       Impact factor: 3.857

Review 8.  Serglycin: at the crossroad of inflammation and malignancy.

Authors:  Angeliki Korpetinou; Spyros S Skandalis; Vassiliki T Labropoulou; Gianna Smirlaki; Argyrios Noulas; Nikos K Karamanos; Achilleas D Theocharis
Journal:  Front Oncol       Date:  2014-01-13       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.